Abeille Pharmaceuticals

Abeille Pharmaceuticals was a specialty pharmaceutical company based in Princeton, New Jersey, focused on developing innovative drug delivery systems for existing therapeutic agents. The company utilized proprietary technologies to create reformulated products, primarily in the areas of oncology supportive care and metabolic diseases. Its most significant achievement was the development of AP-102, a transdermal patch delivery system for the 5-HT3 receptor antagonist granisetron. AP-102 was licensed to ProStrakan Group and subsequently received FDA approval as Sancuso for the prevention of chemotherapy-induced nausea and vomiting. The company's strategy centered on improving patient compliance and therapeutic outcomes through non-invasive delivery methods.